Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTYXH1)

Drug Name

3-Aminomethyl-5-methyl-hexanoic acid Drug Info

Synonyms

3-(aminomethyl)-5-methylhexanoic acid; 128013-69-4; 130912-52-6; rac-Pregabalin; 3-(Aminomethyl)-5-methylhexanoicacid; 3-(aminomethyl)-5-methyl-hexanoic acid; Hexanoic acid,3-(aminomethyl)-5-methyl-; Hexanoic acid, 3-(aminomethyl)-5-methyl-; AYXYPKUFHZROOJ-UHFFFAOYSA-N; NCGC00095186-01; AC1NFWUF; PubChem15652; ACMC-20p1cu; ACMC-1CF05; SCHEMBL15497; CHEMBL88034; PHARMA-0589; KS-00000AKV; CTK4B5836; BCP17115; BCP05685; BBL100350; CA-452; FC0023; ANW-51583; STK894330

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 4715169
TTD Drug ID: DMTYXH1

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Investigative Drug(s)

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Voltage-gated calcium channel alpha-2/delta-3 (CACNA2D3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PD-144550	DM03526	Discovery agent	N.A.	Investigative	[1]
------------------------------------------------------------------------------------

Drug(s) Targeting Voltage-gated calcium channel alpha-2/delta-2 (CACNA2D2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PD-144550	DM03526	Discovery agent	N.A.	Investigative	[1]
------------------------------------------------------------------------------------

Drug(s) Targeting Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Diltiazem	DMAI7ZV	Angina pectoris	BA40	Approved	[2]
Nitrendipine	DM21C09	Hypertension	BA00-BA04	Approved	[3]
Lercanidipine	DMPWSEM	Hypertension	BA00-BA04	Approved	[4]
Pregabalin	DMDVP3B	Chronic obstructive pulmonary disease	CA22	Approved	[5]
Amlodipine	DMBDAZV	Angina pectoris	BA40	Approved	[6]
Mirogabalin	DM5GIWZ	Peripheral neuropathy	8C0Z	Registered	[7]
Imagabalin	DMRLVUD	Generalized anxiety disorder	6B00	Phase 3	[8]
NP-118809	DM8A64W	Pain	MG30-MG3Z	Discontinued in Phase 2	[9]
PD-144550	DM03526	Discovery agent	N.A.	Investigative	[1]
(S)-2-amino-3-cyclohexylpropanoic acid	DM1GBX8	Discovery agent	N.A.	Investigative	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)	TTFK1JQ	CA2D1_HUMAN	Inhibitor	[1]
Voltage-gated calcium channel alpha-2/delta-2 (CACNA2D2)	TTU8P3M	CA2D2_HUMAN	Inhibitor	[1]
Voltage-gated calcium channel alpha-2/delta-3 (CACNA2D3)	TTN7T29	CA2D3_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Enantioselective synthesis of PD144723: a potent stereospecific anticonvulsant, Bioorg. Med. Chem. Lett. 4(6):823-826 (1994).
2	Egr-1, the potential target of calcium channel blockers in cardioprotection with ischemia/reperfusion injury in rats. Cell Physiol Biochem. 2009;24(1-2):17-24.
3	Sulfobutyl ether-alkyl ether mixed cyclodextrin derivatives with enhanced inclusion ability. J Pharm Sci. 2009 Dec;98(12):4769-80.
4	Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine Expert Opin Drug Metab Toxicol. 2009 Aug;5(8):981-7.
5	Pregabalin reduces the release of synaptic vesicles from cultured hippocampal neurons. Mol Pharmacol. 2006 Aug;70(2):467-76.
6	A first drug combination for the treatment of arterial hypertension with a calcium channel antagonist (amlodipine besylate) and an angiotensin receptor blocker (valsartan): Exforge. Rev Med Liege. 2007 Nov;62(11):688-94.
7	Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study. Diabetes Care. 2014 Dec;37(12):3253-61.
8	Methodology for rapid measures of glutamate release in rat brain slices using ceramic-based microelectrode arrays: basic characterization and drug pharmacology. Brain Res. 2011 Jul 15;1401:1-9.
9	Scaffold-based design and synthesis of potent N-type calcium channel blockers. Bioorg Med Chem Lett. 2009 Nov 15;19(22):6467-72.
10	Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41.